His primary areas of study are Internal medicine, Transplantation, Kidney transplantation, Surgery and Immunology. His biological study spans a wide range of topics, including Gastroenterology and Ribavirin. His studies in Transplantation integrate themes in fields like Clinical endpoint, Randomized controlled trial, Cohort and Sirolimus.
His Kidney transplantation study combines topics in areas such as Therapeutic drug monitoring, Regimen, Pathology, Nephropathy and Ciclosporin. The concepts of his Surgery study are interwoven with issues in Immunosuppression, Urology and Renal function. His Immunology research is multidisciplinary, incorporating perspectives in Liver disease, Organ transplantation and Hepatitis E virus.
His main research concerns Internal medicine, Transplantation, Kidney transplantation, Surgery and Gastroenterology. His Internal medicine study integrates concerns from other disciplines, such as Immunology and Hepatitis C virus. He focuses mostly in the field of Transplantation, narrowing it down to matters related to Urology and, in some cases, Tacrolimus, Everolimus and Kidney transplant.
The study incorporates disciplines such as Immunosuppression, Rituximab, Mycophenolic acid and Calcineurin in addition to Kidney transplantation. He works mostly in the field of Surgery, limiting it down to concerns involving Renal function and, occasionally, Creatinine. His Gastroenterology study combines topics from a wide range of disciplines, such as Ribavirin, Anemia and Pathology.
Lionel Rostaing focuses on Kidney transplantation, Internal medicine, Gastroenterology, Urology and Immunosuppression. Transplantation, Kidney and Surgery are inherently bound to his Kidney transplantation studies. His work deals with themes such as Antibody, Rituximab and Oncology, which intersect with Internal medicine.
The various areas that Lionel Rostaing examines in his Gastroenterology study include Daclatasvir, Incidence, Sofosbuvir, Group B and Group A. Lionel Rostaing focuses mostly in the field of Urology, narrowing it down to topics relating to Renal function and, in certain cases, Kidney disease, Kidney donation and Creatinine. As a part of the same scientific family, Lionel Rostaing mostly works in the field of Immunosuppression, focusing on Belatacept and, on occasion, Abatacept.
The scientist’s investigation covers issues in Kidney transplantation, Internal medicine, Tacrolimus, Transplantation and Urology. The subject of his Kidney transplantation research is within the realm of Surgery. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Hepatitis C virus and Virology.
He has researched Tacrolimus in several fields, including Extended release, Pharmacogenetics and Mycophenolic acid. His Transplantation research is multidisciplinary, incorporating perspectives in Immunology, Treatment outcome, Multiple drug resistance and Isoantibodies. His Urology study combines topics from a wide range of disciplines, such as Pharmacokinetics, CYP3A5 and Confidence interval.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Hepatitis E virus and chronic hepatitis in organ-transplant recipients.
Nassim Kamar;Janick Selves;Jean-Michel Mansuy;Leila Ouezzani.
The New England Journal of Medicine (2008)
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).
F. Vincenti;B. Charpentier;Y. Vanrenterghem;L. Rostaing.
American Journal of Transplantation (2010)
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus.
F. Vincenti;S. Friman;E. Scheuermann;L. Rostaing.
American Journal of Transplantation (2007)
Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults
Véronique Fremeaux-Bacchi;Fadi Fakhouri;Arnaud Garnier;Frank Bienaimé.
Clinical Journal of The American Society of Nephrology (2013)
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants.
Nassim Kamar;Nassim Kamar;Cyril Garrouste;Elizabeth B Haagsma;Valérie Garrigue.
Sirolimus Therapy after Early Cyclosporine Withdrawal Reduces the Risk for Cancer in Adult Renal Transplantation
Josep M. Campistol;Josette Eris;Rainer Oberbauer;Peter Friend.
Journal of The American Society of Nephrology (2006)
Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation
Sylvie Euvrard;Emmanuel Morelon;Emmanuel Morelon;Lionel Rostaing;Eric Goffin.
The New England Journal of Medicine (2012)
Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients
Nassim Kamar;Jacques Izopet;Simona Tripon;Michael Bismuth.
The New England Journal of Medicine (2014)
Belatacept and Long-Term Outcomes in Kidney Transplantation.
Flavio Vincenti;Lionel Rostaing;Joseph Grinyo;Kim Rice.
The New England Journal of Medicine (2016)
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.
Y. Le Meur;M. Büchler;A. Thierry;S. Caillard.
American Journal of Transplantation (2007)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: